Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Genmab A/S

    NASDAQ: GMAB · Real-Time Price · USD
    22.81
    -0.28 (-1.21%)
    At close: Jun 13, 2025, 3:59 PM
    22.85
    0.18%
    After-hours: Jun 13, 2025, 05:05 PM EDT
    -1.21%
    Bid 21.8
    Market Cap 14.05B
    Revenue (ttm) 18.1B
    Net Income (ttm) 6.71B
    EPS (ttm) 1.7
    PE Ratio (ttm) 13.42
    Forward PE 1.74
    Analyst Buy
    Ask 23.46
    Volume 1,056,269
    Avg. Volume (20D) 1,424,949
    Open 22.96
    Previous Close 23.09
    Day's Range 22.70 - 23.08
    52-Week Range 17.23 - 28.56
    Beta 0.82

    About GMAB

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol GMAB
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for GMAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 week ago
    +3.91%
    Genmab shares are trading higher after the company... Unlock content with Pro Subscription
    2 months ago
    +2.65%
    Genmab A/S shares are trading higher after the company announced that the Japan Ministry of Health, Labour and Welfare has approved TIVDAK.
    news image

    1 week ago · fool.com

    Why Genmab Stock Smashed It on Monday

    On a generally upbeat Monday for the stock market, investors weren't only buying into U.S. companies. Quite a few of them also piled into the American Depositary Receipts (ADRs) of Danish biotech Genm...

    news image

    1 week ago · businesswire.com

    Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial

    COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today new data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S®), an investigational...

    news image

    3 weeks ago · businesswire.com

    Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

    COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that it will present new research from its comprehensive development program evaluating its late-stage portfolio at the ...

    news image

    3 weeks ago · seekingalpha.com

    Genmab A/S: Transitioning From Royalty Model To Commercial-Stage Oncology

    Genmab has promising proprietary antibody platforms and partnerships that have helped it transition from licensor to commercial-stage biotech. Their robust royalty stream from Darzalex and Kesimpta fu...

    news image

    1 month ago · businesswire.com

    Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

    COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that it will present 14 abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneou...

    news image

    1 month ago · businesswire.com

    Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

    COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to the U.S. Food a...

    news image

    1 month ago · zacks.com

    GMAB or RGEN: Which Is the Better Value Stock Right Now?

    Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Genmab A/S Sponsored ADR (GMAB) and Repligen (RGEN). But which of these two stocks is more attractive to value...

    news image

    1 month ago · zacks.com

    Should Value Investors Buy Genmab (GMAB) Stock?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

    news image

    1 month ago · seekingalpha.com

    Genmab's Outlook Beyond Darzalex's Patent Cliff

    Genmab presents a long-term investment opportunity, but uncertainties around Darzalex's pending patent expiration warrant a cautious approach. The company's robust late-stage pipeline could offset DAR...

    news image

    2 months ago · businesswire.com

    TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

    COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug ...

    Add to Watchlist